Taken together, these observations indicate that SHCBP1 may serves not only as a surrogate marker for tumor aggressiveness, but also as an integrative indicator of molecular subtype, immune evasion, and therapeutic response. The gene discussed is SHCBP1; the disease is neoplasm.